Summary statistics - qualitative results

EQA round: IGIT2/23 - Immunopathology of GIT

Deadline: 23.10.2023

Setup: groups - measurement principle

AV = assigned value
CVP = consensus of all participants
>>> ... expected result
> ... acceptable result
± ... result not assessed

N_{tot} = total number of the results
N_{rel} = relative number of the results

N_{eva} = number of the results assessed
N_{suc} = number of successful results
S_{rel} = relative success

Test / Sample / Group	AV	N_{tot}	N_{rel} [%]	Result	N_{eva}	N_{suc}	S_{rel} [%]
Set 1							
(595) **anti-gliadin IgA (deamidated)**		72			72	72	100
Sample A1		72			72	72	100
(1) Fluorescent methods	CVP >>>	1	1,4	Negative			
(2) EIA methods	CVP >>>	56	78	Negative			
(5) LIA, ILMA	CVP >>>	11	15	Negative			
(99) Another measurement principle	CVP >>>	4	5,6	Negative			
Sample B1		72			72	72	100
(1) Fluorescent methods	CVP >>>	1	1,4	Positive			
(2) EIA methods	CVP >>>	56	78	Positive			
(5) LIA, ILMA	CVP >>>	11	15	Positive			
(99) Another measurement principle	CVP >>>	4	5,6	Positive			
(594) **anti-gliadin IgG (deamidated)**		75			75	73	97
Sample A1		75			75	75	100
(1) Fluorescent methods	CVP >>>	1	1,3	Negative			
(2) EIA methods	CVP >>>	58	77	Negative			
(5) LIA, ILMA	CVP >>>	12	16	Negative			
(99) Another measurement principle	CVP >>>	4	5,3	Negative			
Sample B1		75			75	73	97
(1) Fluorescent methods	CVP >>>	1	1,3	Positive			
(2) EIA methods		1	1,3	Negative			
		1	1,3	Inconclusive result (borderline)			
	CVP >>>	56	75	Positive			
(5) LIA, ILMA	CVP >>>	12	16	Positive			
(99) Another measurement principle	CVP >>>	4	5,3	Positive			
(421) **anti-gliadin IgA (native)**		16			16	15	94
Sample A1		16			16	16	100
(2) EIA methods	CVP >>>	16	100	Negative			
Sample B1		16			16	15	94
(2) EIA methods		1	6,3	Inconclusive result (borderline)			
	CVP >>>	15	94	Positive			
(420) **anti-gliadin IgG (native)**		16			16	15	94
Sample A1		16			16	16	100
(2) EIA methods	CVP >>>	16	100	Negative			
Sample B1		16			16	15	94
(2) EIA methods		1	6,3	Inconclusive result (borderline)			
	CVP >>>	15	94	Positive			
Set 2							
(424) **anti-endomysium IgA**		72			72	71	99
Sample A2		72			72	71	99
(1) Fluorescent methods	CVP >>>	70	97	Negative			
		1	1,4	Positive			
(2) EIA methods	CVP >>>	1	1,4	Negative			
Sample B2		72			72	72	100
(1) Fluorescent methods	CVP >>>	71	99	Positive			
(2) EIA methods	CVP >>>	1	1,4	Positive			
(425) **anti-transglutaminase IgA**		84			84	84	100
Sample A2		84			84	84	100
(1) Fluorescent methods	CVP >>>	1	1,2	Negative			
(2) EIA methods	CVP >>>	62	74	Negative			
(5) LIA, ILMA	CVP >>>	18	21	Negative			
(99) Another measurement principle	CVP >>>	3	3,6	Negative			
Sample B2		84			84	84	100
(1) Fluorescent methods	CVP >>>	1	1,2	Positive			
(2) EIA methods	CVP >>>	62	74	Positive			
(5) LIA, ILMA	CVP >>>	18	21	Positive			
(99) Another measurement principle	CVP >>>	3	3,6	Positive			
Set 3							
(592) **anti-Saccharomyces cerevisiae IgA**		65			0		
Sample A3		65			65	64	98
(1) Fluorescent methods		1	1,5	Negative			
	CVP >>>	22	34	Positive			

Summary statistics - qualitative results

EQA round: IGIT2/23 - Immunopathology of GIT

Deadline: 23.10.2023

Setup: groups - measurement principle

Test / Sample / Group	AV	N_{tot}	N_{rel} [%]	Result	N_{eva}	N_{suc}	S_{rel} [%]
(2) EIA methods	CVP >>>	40	62	Positive			
(5) LIA, ILMA	CVP >>>	1	1,5	Positive			
(99) Another measurement principle	CVP >>>	1	1,5	Positive			
Sample B3		65			0		
(1) Fluorescent methods	±	8	12	Negative			
	±	5	7,7	Inconclusive result (borderline)			
	±	10	15	Positive			
(2) EIA methods	±	4	6,2	Negative			
	±	36	55	Positive			
(5) LIA, ILMA	±	1	1,5	Positive			
(99) Another measurement principle	±	1	1,5	Positive			
(593) **anti-Saccharomyces cerevisiae IgG**		58			58	54	93
Sample A3		58			58	58	100
(1) Fluorescent methods	CVP >>>	20	34	Positive			
(2) EIA methods	CVP >>>	36	62	Positive			
(5) LIA, ILMA	CVP >>>	1	1,7	Positive			
(99) Another measurement principle	CVP >>>	1	1,7	Positive			
Sample B3		58			58	54	93
(1) Fluorescent methods	CVP >>>	18	31	Negative			
		2	3,4	Inconclusive result (borderline)			
(2) EIA methods	CVP >>>	34	59	Negative			
		2	3,4	Positive			
(5) LIA, ILMA	CVP >>>	1	1,7	Negative			
(99) Another measurement principle	CVP >>>	1	1,7	Negative			